Back to Search
Start Over
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
- Source :
- Journal for Immunotherapy of Cancer, Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
- Publication Year :
- 2017
-
Abstract
- Background Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. Methods All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables. Results A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median follow-up 61 months), the estimated median recurrence-free survival was 45 months, while the median overall survival was not yet reached. In the control cohort of 123 patients (median follow-up 30 months), the estimated median recurrence-free and overall survival were 22 and 58 months, respectively. Within the retrospective stage III cohort, NY-ESO-1 vaccine was associated with decreased risk of recurrence (HR = 0.56, p
- Subjects :
- 0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Immunology
lcsh:RC254-282
Cancer Vaccines
Cancer Testis Antigen
03 medical and health sciences
0302 clinical medicine
Internal medicine
PD-1
medicine
Adjuvant therapy
Immunology and Allergy
Humans
NY-ESO-1
Stage (cooking)
Melanoma
Adjuvant
Pharmacology
business.industry
Retrospective cohort study
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Clinical trial
030104 developmental biology
Nivolumab
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Cohort
Molecular Medicine
Female
CTLA-4
Immunotherapy
business
Tumor antigen
Vaccine
Research Article
Subjects
Details
- ISSN :
- 20511426
- Volume :
- 6
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal for immunotherapy of cancer
- Accession number :
- edsair.doi.dedup.....d622ce36ba867fe972b73a8708d05482